BioNexus Gene Lab News

News

Ticker

BGLC

ISIN

US0906283066

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

BioNexus Gene Lab Eulerpool News

BioNexus Gene Lab Stock News

BioNexus Gene Lab is being monitored by journalists and investors worldwide. We gather the latest BioNexus Gene Lab news here.

January 28·
Benzinga
BioNexus Gene Lab Commences Its 2026 Deployment Phase For VitaGuard Minimal Residual Disease Platform
December 23·
Benzinga
BioNexus Gene Lab Names Matthew L. Barsing As Chairman Of The Board
December 8·
Benzinga
12 Industrials Stocks Moving In Monday's After-Market Session
December 4·
Benzinga
12 Industrials Stocks Moving In Thursday's Pre-Market Session
December 2·
Benzinga
BioNexus Gene Lab Corp Secures$500M Equity Facility From ARC Group
December 1·
Yahoo
BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene
November 10·
Yahoo
BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities
November 10·
Benzinga
BioNexus Gene Lab Files $100M Shelf Registration And Establishes $20M ATM Program To Support Growth In Precision Oncology And Gene-Based Technologies
November 3·
Benzinga
12 Industrials Stocks Moving In Monday's Pre-Market Session
October 20·
Benzinga
BioNexus Gene shares are trading higher after the company announced a partnership with BirchBioMed to lead its $10 million funding round through an equity investment and collaboration.
July 17·
Benzinga
12 Industrials Stocks Moving In Thursday's Intraday Session
July 2·
Yahoo
US Futures Subdued as Investors Eye Key Employment Data
July 2·
Benzinga
Why Greenbrier Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
June 6·
SeekingAlpha
VanEck Crypto Monthly Recap For May 2025
May 12·
Benzinga
Shares of companies in the broader industrial sector are trading higher amid overall market strength after the US and China agreed to a temporary reduction in most tariffs on each other's goods. This could reduce macro uncertainty that has weighed on economic outlook.
April 22·
Benzinga
Bitcoin Is Steel, Ethereum And Solana Are Balsa Wood And Clay, Warns Michael Saylor—Strategy Chair Says Leveraging ETH, SOL Could Lead To 'Catastrophe'
March 8·
Yahoo
Bionexus Gene Lab enters partnership with ML Tech
March 7·
Benzinga
BioNexus Gene Lab Announces A Strategic Partnership With ML Tech To Optimize The BGLC's Ethereum-Based Growth Strategies
October 14·
Benzinga
12 Industrials Stocks Moving In Monday's After-Market Session
September 25·
Yahoo
BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.

BioNexus Gene Lab Stock Press Releases

BioNexus Gene Lab regularly publishes news on the company's website that are relevant for investors.

December 14•
BioNexus Gene Lab
Bionexus Gene Lab Corp to Webcast Live at Life Sciences Investor Forum December 17th

BioNexus Gene Lab News 2026

This page contains all current news, analysis and press releases for BioNexus Gene Lab stock (BGLC, ISIN: US0906283066). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at BioNexus Gene Lab.

BioNexus Gene Lab Stock

BioNexus Gene Lab BioNexus Gene Lab Corp. develops and markets non-invasive blood tests for early disease detection, analyzing RNA changes to assess risks for over 11 diseases. The company’s subsidiary, Bionexus Gene Lab Sdn. Bdh., supports these operations. Products are sold to healthcare providers and diagnostic centers seeking advanced, non-invasive testing solutions. The firm targets medical professionals and institutions focused on personalized health management through functional genomics applications. The company generates revenue through the sale of its RNA-based blood tests, which are marketed as tools for early disease risk assessment. Healthcare institutions and diagnostic service providers purchase these tests to enhance their diagnostic capabilities. The focus on non-invasive methods aligns with growing demand for patient-friendly diagnostic technologies in the molecular diagnostics sector. BioNexus Gene Lab Corp. operates with a small team of 5 full-time employees, emphasizing efficiency in product development and marketing. The subsidiary Bionexus Gene Lab Sdn. Bdh. facilitates local operations, though specific market segments are not detailed beyond healthcare providers and diagnostic centers. Revenue streams are derived solely from test sales, with no mention of additional services or partnerships.